Keyphrases
CpG ODN
100%
Glycoprotein
100%
Non-glycosylated
100%
Eosinophilia
100%
Respiratory Syncytial Virus
100%
Virus Challenge
75%
Specific Antibodies
50%
Recombinant Glycoprotein
50%
Lung
25%
Adverse Reactions
25%
T Helper 1
25%
Combination Vaccine
25%
Clinical Application
12%
G Protein
12%
Viral Load
12%
Escherichia Coli
12%
Cell Adhesion
12%
Recombinant
12%
Highly Effective
12%
Infiltrating Cells
12%
Increased Safety
12%
Upper Respiratory Tract
12%
Mammalian Cells
12%
Lung Inflammation
12%
Lung Pathology
12%
T Cell Response
12%
Vaccination
12%
Single Antigen
12%
Vaccine Types
12%
Vaccine Target
12%
Vaccine Antigen
12%
AddaVax
12%
Pulmonary Inflammation
12%
Enhanced Efficacy
12%
Attachment Glycoprotein
12%
Antigen Candidate
12%
Cell Pathology
12%
Aluminum Salts
12%
Antigen Vaccine
12%
Enhanced Respiratory Disease
12%
Nasal Turbinate
12%
Respiratory Syncytial Virus Vaccines
12%
Pharmacology, Toxicology and Pharmaceutical Science
CpG Oligodeoxynucleotide
100%
Glycoprotein
100%
Eosinophilia
100%
Human Respiratory Syncytial Virus
100%
Antibodies
36%
Adjuvant
27%
Adverse Event
18%
Pneumonia
18%
Combination Vaccine
18%
Disease
9%
Guanine Nucleotide Binding Protein
9%
Escherichia coli
9%
Respiratory Tract
9%
Infection
9%
Respiratory Syncytial Virus Vaccine
9%
Aluminium Salt
9%
Immunology and Microbiology
Glycoprotein
100%
CpG Oligodeoxynucleotide
100%
Human Respiratory Syncytial Virus
100%
Antibodies
36%
Adjuvant
27%
Pulmonary Inflammation
18%
T Helper 1 Cell
18%
T Cell
9%
Viral Load
9%
Escherichia coli
9%
Cell Adhesion
9%
Upper Respiratory Tract
9%
Respiratory Syncytial Virus Vaccine
9%
Turbinate
9%
Immunology
9%